2019 American Transplant Congress
Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients
*Purpose: Letermovir is a new antiviral recently approved for cytomegalovirus (CMV) prophylaxis in CMV-seropositive hematopoietic-cell transplant recipients. Its off-label use in solid organ transplant (SOT)…2019 American Transplant Congress
Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir
*Purpose: Studies evaluating the efficacy of valganciclovir (VGC) at 450 mg daily versus 900 mg daily for the prevention of cytomegalovirus (CMV) in kidney transplant…2019 American Transplant Congress
Target Itraconazole Trough Concentration for Prophylaxis in Lung Transplant
*Purpose: Itraconazole (ITR) therapeutic drug monitoring (TDM) for prophylaxis in lung transplant recipients (LTR) is not well characterized. Our purpose was to evaluate ITR trough…2019 American Transplant Congress
Outbreak of Pneumocystis Pneumonia in a Transplant Center Linked to a Single Genotype of Pneumocystis jirovecii: Effects of Cytomegalovirus Infection and Allograft Rejection
*Purpose: Although post-transplant pneumocystis pneumonia (PCP) outbreaks have been reported from Asia, Australia and Europe, there are limited data from North America. We investigated transmissibility…2018 American Transplant Congress
Itraconazole Prophylaxis, Trough Concentration, and Identification of Fungal Pathogens in Lung Transplant
Cleveland Clinic Foundation, Cleveland, OH.
Studies of prophylactic itraconazole (ITR) in lung transplant recipients (LTR) are lacking. Our purpose was to evaluate LTR who received ITR prophylaxis and the association…2018 American Transplant Congress
Incidence of Atrial Arrhythmia after Lung Transplantation with a Universal Prophylaxis Strategy
PurposePostoperative atrial arrhythmias (AA) occur in 19-39% of patients after lung transplantation and are associated with increased mortality, hospital length of stay, and risk of…2018 American Transplant Congress
Evaluation of a Change in CMV Prevention Strategy Following Pediatric SOT
Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Optimal cytomegalovirus(CMV) prevention strategy following solid organ transplantation(SOT) is uncertain. We report on CMV disease with implementation of prophylaxis-based prevention with intensive monitoring.We retrospectively evaluated…2018 American Transplant Congress
Efficacy of Two Valganciclovir Dosing Strategies in Intermediate and High-Risk Liver Transplant Recipients
Purpose: There is interest in reduced dosing and duration of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant (LT) recipients to minimize side effects…2018 American Transplant Congress
Impact of Positive Donor Blood Cultures in Liver Transplant Recipients
Emory University Hospital, Atlanta, GA.
The purpose of this study was to describe the bacteremia transmission rate of transplanting livers from donors with positive bacterial blood cultures into liver transplant…2018 American Transplant Congress
Early versus Late Cytomegalovirus Prophylaxis after Kidney Transplant
Duke University Hospital, Durham, NC.
Background: Prophylaxis against cytomegalovirus (CMV) is recommended in high-risk patients (CMV D+/R-) and those who are CMVR+ and getting T-cell depletional therapy. It is unclear…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 14
- Next Page »